gip/glp-1 tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Unveiling Tirzepatide's Therapeutic Spectrum: A
Description
Some plans exclude weight loss medications altogether
The employer benefits too, because carriers offer discounts to companies that can show they are actively investing in workforce health, the same way they do with smoking cessation programs
Seek a personalised and gradual approach to weight loss
Below are a few thoughts to consider as you plan for 2024 and beyond
A 2024 meta-analysis (Sattar et al., Lancet Diabetes Endocrinol) found that switching from semaglutide to tirzepatide produced an additional 4.2 kg mean weight loss over 40 weeks, even when semaglutide had been titrated to maximum dose
Differential Role of Transforming Growth Factor-beta in an Osteoarthritic or a Healthy Joint
